Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.

被引：1
|
作者：
Biran, Noa
Siegel, David Samuel DiCapua
Berdeja, Jesus G.
Raje, Noopur S.
Cornell, Robert F.
Alsina, Melissa
Kovacsovics, Tibor
Fang, Belle
Kimball, Amy
Landgren, Carl Ola
机构：
[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Huntsman Canc Inst, Salt Lake City, UT USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8022
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Economic evaluation of carfilzomib plus lenalidomide plus dexamethasone (KRd) vs. lenalidomide plus dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
    Jakubowiak, Andrzej J.
    Benedict, Agnes
    Panjabi, Sumeet
    Houisse, Ivan
    Campioni, Marco
    Giannopoulou, Andromachi
    Aggarwal, Sanjay
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CAMPANIA REGION: A ONE-YEAR SURVEY
    Palmieri, S.
    Rocco, S.
    Migliaccio, I.
    Cerchione, C.
    Catalano, L.
    Ferrara, K.
    Peluso, I.
    Monaco, G.
    Farina, G.
    Gagliardi, A.
    Barone, M.
    Esposito, D.
    Amico, V.
    Arcamone, M.
    Fontana, R.
    Sica, A.
    Pane, F.
    Ferrara, F.
    HAEMATOLOGICA, 2017, 102 : 126 - 126
  • [33] A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
    Bhutani, Manisha
    Foureau, David M.
    Robinson, Myra
    Guo, Fei
    Fesenkova, Kateryna
    Atrash, Shebli
    Paul, Barry
    Varga, Cindy
    Friend, Reed
    Pineda-Roman, Mauricio
    Rigby, Katherine
    Symanowski, James T.
    Norek, Sarah
    Tucker, Mallory R.
    Druhan, Lawrence J.
    Voorhees, Peter M.
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (07): : 535 - +
  • [34] Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
    Landgren, Ola
    Alsina, Melissa
    Biran, Noa
    Vesole, David H.
    Wallace, Paul K.
    Fang, Belle
    Arnold, Gregory
    Kimball, Amy
    Siegel, David S.
    BLOOD, 2020, 136
  • [35] CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael
    Tzachanis, Dimitrios
    Agajanian, Richy
    Boccia, Ralph
    Coleman, Morton
    Moss, Robert A.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Anderl, Janet
    Aggarwal, Sanjay
    Berdeja, Jesus G.
    BLOOD, 2016, 127 (26) : 3360 - 3368
  • [36] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Ray
    Wang, Jim
    Masterson, Tara
    Nottage, Kerri
    Schecter, Jordan
    Chiu, Christopher
    Khokhar, Nushmia
    Ahmadi, Tahamtan
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
  • [37] Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
    Jakubowiak, Andrzej J.
    Chari, Ajai
    Lonial, Sagar
    Weiss, Brendan M.
    Comenzo, Raymond L.
    Wu, Kaida
    Khokhar, Nushmia Z.
    Wang, Jianping
    Doshi, Parul
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
    Mikhael, Joseph
    Richardson, Paul
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Karanes, Chatchada
    Campana, Frank
    Kanagavel, Dheepak
    Dubin, Franck
    Liu, Qianying
    Semiond, Dorothee
    Anderson, Kenneth
    BLOOD, 2019, 134 (02) : 123 - 133
  • [39] PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Diehl, S.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Zhu, M.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2016, 101 : 81 - 82
  • [40] Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael A.
    Tzachanis, Dimitrios
    Coleman, Morton
    Boccia, Ralph V.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Berdeja, Jesus G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345